Abstracts Archive - Page 120 of 2607 - ACR Meeting Abstracts

Abstract Number: 1440 • ACR Convergence 2025
Comparison of standard and tapered dose of biologic treatments in patients with axial spondyloarthritis
MÜSLÜM FIRAT İKİKARDEŞ¹, EMRAH KOÇ¹, gEZMIS KIMYON², EMİNE DUYGU ERSOZLU¹ and TAYYIBE SALER¹, ¹ADANA SEHİR HASTANESİ, ADANA, Turkey, ²MUSTAFA KEMAL UNIVERSITY, HATAY, Turkey
Background/Purpose: We aimed to compare the demographic and clinical characteristics of the patients with axial spondyloarthritis (aSpA) receiving standard-dose versus tapered-dose biologic disease-modifying antirheumatic drugs…
Abstract Number: 1460 • ACR Convergence 2025
Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
Stefan Siebert¹, Mohamed Sharaf², Frank Behrens³, Proton Rahman⁴, mitsumasa kishimoto⁵, Enrique R. Soriano⁶, Emmanouil Rampakakis⁷, László Köleséri⁸, Karissa Lozenski⁹, Ruben Queiro¹⁰, Ennio Lubrano¹¹ and Laure Gossec¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen - Johnson & Johnson, Dubai, United Arab Emirates, ³Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, ⁴Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁵Kyorin University School of Medicine, Tokyo, Japan, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁷JSS Medical Research, Montréal, QC, Canada, ⁸IQVIA, Budapest, Hungary, ⁹Johnson & Johnson, Horsham, PA, ¹⁰Hospital Universitario Central de Asturias, Oviedo. Asturias, Spain, ¹¹Department of Medicine, Università deglia Studi del Molise, CAMPOBASSO, Italy, ¹²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France
Background/Purpose: Work impairment is a key issue in PsA. Biologic treatments can improve work status in patients (pts) with PsA; however, there is lack of…
Abstract Number: 1300 • ACR Convergence 2025
International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
Chandni Sarker¹, Jennifer Cooper², Emily Smitherman³, Flavia Alves¹, Alexandre Belot⁴, Michael Beresford⁵, Andreea Jorgensen¹, Eve Smith⁶, Laura Lewandowski⁷ and Rebecca Sadun⁸, ¹University of Liverpool, Liverpool, United Kingdom, ²University of Colorado/Children's Hospital Colorado, Aurora, CO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hospices Civils de Lyon, Collonges au mont d'or, France, ⁵Alder Hey Children's NHS Foundation Trust Hospital, Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷NIAMS, NIH, Bethesda, MD, ⁸Duke University, Durham, NC
Background/Purpose: Consensus-derived treat-to-target (T2T) goals for childhood-onset SLE (cSLE), including clinical remission on low dose steroids (cCR), have been endorsed by the Paediatric Rheumatology European…
Abstract Number: 1580 • ACR Convergence 2025
Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis
Maria Iacovantuono¹, Nicholas landini², lisa Jungblut³, Gesa Sauer⁴, Rucsandra Dobrota⁵, Sinziana Muraru⁶, Muriel Elhai⁷, Carina Mihai⁸, Mike Becker⁹, Maria Sole Chimenti¹⁰, Thomas Frauenfelder³, Anna-Maria Hoffmann-Vold¹¹, Oliver Distler¹² and Cosimo Bruni¹³, ¹Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Spinete, Italy, ²Department of Radiological Sciences, Oncology and Pathology, "Sapienza" University, Policlinico Umberto I, Rome, Italy. Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Rueil Malmaison, France, ³Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, University Zurich, Zurich, Switzerland, zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, zurich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, the LOOP Zurich, Zurich, Switzerland, ⁶University of Zurich, University Hospital Zurich, Zürich, Switzerland, ⁷University Hospital zurich, Zürich, Switzerland, ⁸University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁹Dept. of Rheumatology, University Hospital Zurich, Zürich, Switzerland, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy, Roma, Italy, ¹¹Oslo University Hospital, Oslo, Norway, ¹²Department of Rheumatology, University Hospital Zurich, University of Zurich, Switzerland, Zurich, Switzerland, ¹³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) is highly prevalent in systemic sclerosis (SSc) and a leading cause of mortality. Recent studies have identified clinical risk factors…
Abstract Number: 1576 • ACR Convergence 2025
Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study
kyung-Ann Lee¹, Hyun-Sook Kim² and Boda Nam³, ¹Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea, ²Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea, ³Chung-Ang University Hospital, Seoul, Republic of Korea
Background/Purpose: Pulmonary fibrosis is a recognized sequela of severe COVID-19 pneumonia, but its additive impact on pre-existing interstitial lung disease (ILD)—particularly in patients with connective…
Abstract Number: 1551 • ACR Convergence 2025
Disease Burden and Treatment Preferences for Systemic Lupus Erythematosus: Results from a Global Real-World Survey
Zahi Touma¹, Christopher Saffore², Karim Masri³, Jerry Clewell³, Emily Goddard⁴, Grace O'Neill⁴, Madelane Foxall⁴ and Karen H. Costenbader⁵, ¹University of Toronto, Toronto, ON, Canada, ²AbbVie Inc., waukegan, IL, ³AbbVie Inc., North Chicago, IL, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: As new treatment options for systemic lupus erythematosus (SLE) become available, understanding patient burden and preferences is key to optimizing shared decision-making. This study…
Abstract Number: 1587 • ACR Convergence 2025
Longitudinal Clinical Response to JAK Inhibitors in Systemic Sclerosis: A Real-Life Multicentric Study Across Clinical Domains
Stefano Di Donato¹, JUAN JOSE ALEGRE SANCHO², Anastas Batalov³, Zguro Batalov⁴, Silvia Bellando-Randone⁵, carmela coccia⁶, Marco de Pinto⁷, Dilia Giuggioli⁸ and Michael Hughes⁹, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²Department of rheumatology. Hospital Universitario Doctor Peset, Valencia, Spain, ³Medical University of Plovdiv, Plovdiv, Bulgaria, ⁴UMHAT Kaspela, Ploudiv, Bulgaria, ⁵University of Florence, Florence, Florence, Italy, ⁶Rheumatology Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy, ⁷Azienda Ospedaliero Universitaria Policlinico di Modena, Parma, Parma, Italy, ⁸Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ⁹Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom
Background/Purpose: JAK inhibitors (JAKi) have shown promising early results in systemic sclerosis (SSc) patients, yet real-world data on their longitudinal effects across different disease domains…
Abstract Number: 1548 • ACR Convergence 2025
Anifrolumab In Systemic Lupus Erythematosus. Spanish Multicenter Registry In Clinical Practice
Vanesa Calvo-Río¹, Carmen Secada-Gómez¹, Miriam Retuerto Guerrero², Judit Font-Urgelles³, Ivette Casafont-Solé³, Adrián Mayo-Juanatey⁴, Juan José Alegre-Sancho⁵, DALIFER FREITES⁶, Cristina Hormigos Martin⁷, Noemí Garrido⁸, GUILLERMO GONZALEZ ARRIBAS⁹, Juan Roberto Miguelez Sanchez¹⁰, Andrea García-Valle¹¹, Marta Ibañez¹², Fernando Lozano Morillo¹³, Ángel García Manzanares¹⁴, Sebastián Sandoval-Moreno¹⁵, Josefina Cortés-Hernández¹⁶, Deseada Palma-Sanchez¹⁷, LETICIA LOJO-OLIVEIRA¹⁸, Evelin Cervantes¹⁹, Paz Collado Ramos²⁰, cristina arciniega Larios²¹, Luis Sala²², Eztizen Labrador-Sánchez²³, Cilia Peralta-Ginés²⁴, Nahia Plaza-Aulestia²⁵, Irati Urionaguena Onaindia²⁶, Miguel Medina Malone²⁷, Jose Rosas Gómez de Salazar²⁸, Montserrat Corteguera²⁹, Laura Cebrian³⁰, Fred Anton Pages³¹, Jose Ramón Lamua-Riazuelo³², María Dolores Fábregas Canales³³, María José Alados Hernández³⁴, Marta Garijo Bufort³⁵, Anna Pamies³⁶, Luis Sarabia³⁷, Rodrigo Aguirre-del-Pino³⁸, José Ángel Cabezas Lefler³⁹, alvaro seijas³⁸, Carmen Carrasco-Cubero⁴⁰, Ana López-Cerón Cofiño⁴¹, Vera Ortiz-Santamaria⁴², Santos Castañeda⁴³, Maria Laino⁴⁴, Carmen Ordás Calvo⁴⁵, Celia arconada⁴⁶, ana Urruticoechea-Arana⁴⁷, Blanca Garcia-Magallon⁴⁸, Ana Valeria Acosta Alfaro⁴⁹, Samuel Leal Rodriguez⁵⁰, Marina Salido Olivares⁷, Patricia Lavilla Villar⁵¹, Anahy Maria Brandy³, Inmaculada Ros Vilamajo⁵², Alvaro García Martos⁵³, Berta Magallares⁵⁴, Guillen Sada Urmeneta⁵⁵, Cristina Córdoba Martín⁵⁶, Elena Riera Alonso⁵⁷, Carmen Bejerano-Herreria⁵⁸ and Ricardo Blanco,<58, ¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ²Complejo Asistencial Universitario de Leon, Leon, Castilla y Leon, Spain, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, ⁵Hospital Universitario Doctor Peset, Valencia, Spain, ⁶Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, ⁷Hospital Clínico San Carlos, Madrid, Spain, ⁸Hospital Universitario Virgen del Rocío, Sevilla, Andalucia, Spain, ⁹Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, ¹⁰Department of Rheumatology, Hospital Universtiario de Móstoles, Madrid, Spain, Madrid, Madrid, Spain, ¹¹Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, ¹²Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ¹³Hospital Central de La Defensa Gómez Ulla, Madrid, Madrid, Spain, ¹⁴Hospital Universitario de Torrevieja, Alicante, Spain, ¹⁵Hospital Universitario Vall D'Hebron, Barcelona, Spain, ¹⁶Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, ¹⁷Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁸Hospital Universitario Infanta Leonor, Madrid, Spain, ¹⁹Hospital Provincial de Pontevedra, Pontevedra, Spain, ²⁰Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain, ²¹Hospital de Mérida, Badajoz, Spain, ²²Hospital Universitario de Torrejón, Madrid, Spain, ²³Hospital General de La Rioja, Logroño, Spain, ²⁴Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁵Hospital Galdakao, Vizcaya, Spain, ²⁶Rheumatology.Hospital Galdakao, Vizcaya, Pais Vasco, Spain, ²⁷Hospital de Calahorra, Calahorra, Spain, ²⁸Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁹Rheumatology. Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, ³⁰Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ³¹Hospital General de Segovia, Segovia, Spain, ³²Hospital Universitario del Henares, Madrid, Spain, ³³Hospital de Barbastro, Huesca, Spain, ³⁴Hospital Universitario Puerta del Mar, Cadiz, Spain, ³⁵Hospital de Sagunto, Valencia, Spain, ³⁶Hospital Verge de la Cinta, Tortosa, Tarragona, Spain, ³⁷Complejo Hospitalario de Jaén, Jaén, Spain, ³⁸Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁹Complejo Asistencial de Zamora, Zamora, Spain, ⁴⁰Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁴¹Hospital Santa Bárbara, Soria, Spain, ⁴²Hospital General de Granollers, Barcelona, Spain, ⁴³Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁴⁴Hospital Universitario de Navarra, Pamplona, Spain, ⁴⁵Hospital Universitario de Cabueñes, Gijón, Spain, ⁴⁶Hospital universitario de Getafe, Getafe, Madrid, Spain, ⁴⁷Rheumatology Division. Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴⁸Rheumatology, Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁴⁹Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ⁵⁰Hospital Universitario La Fe, Valencia, Valencia, Spain, ⁵¹Hospital General de Villalba, Collado Villalba, Madrid, Spain, ⁵²Hospital Son Llàtzer, Palma de Mallorca, Spain, ⁵³Hospital del Tajo, Aranjuez, Madrid, Spain, ⁵⁴Hospital de Sant Pau, Barcelona, Spain, ⁵⁵Rheumatology, Hospital Reina Sofía, Tudela, Spain, ⁵⁶Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Tenerife, Spain, ⁵⁷Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁵⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.

Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody that binds to the type I interferon receptor subunit 1 (IFNAR1). ANI was approved by Spanish authorities…
Abstract Number: 1577 • ACR Convergence 2025
Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).
Luc Mouthon¹, David Launay², Sylvie leroy³, Christian AGARD⁴, Yannick Allanore⁵, Alice berezne¹, Emmanuel Bergot⁶, Boris Bienvenu⁷, Benjamin Chaigne¹, Pascal Cohen⁸, Bruno Crestani⁹, Anca Corondan¹⁰, bertrand Dunogue¹, Christian Lavigne¹¹, Jonathan London¹², Jean-Marc Naccache¹⁰, Gabriel Baron¹³, Alexis REGENT¹⁴, Benjamin Terrier¹⁵, Zahir AMOURA¹⁶, Charles Marquette¹⁰ and Philippe Ravaud¹³, ¹Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²Univ. Lille, Inserm, CHU Lille, Department of Internal Medicine and Clinical Immunology, Reference Center for Rare Autoimmune and Autoinflammatory diseases (CERAINOM), U¹²⁸⁶ - INFINITE - Institute for Translational Research in Inflammation, Lille, France. National Reference Center for Pulmonary Arterial Hypertension (Pulmotension), Lille, France, Lille Cedex, France, ³AP HP, Paris, France, ⁴Internal medicine, Nantes University Hospital, Nantes, France, ⁵Université Paris Cité, Paris, France, ⁶CHU, Caen, France, ⁷Saint Joseph Hospital, Marseille, France, ⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁹CHU, Paris, France, ¹⁰NA, Paris, France, ¹¹CHU, Angers, France, ¹²Hôpital Croix-Saint-Simon, Paris, France, ¹³Hôtel-Dieu, Université Paris Cité,, Paris, France, ¹⁴Hopital Cochin, Paris, France, ¹⁵Cochin Hospital, Paris, France, ¹⁶APHP, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in patients with systemic sclerosis (SSc). Randomized controlled trials favoured the use of cyclophosphamide…
Abstract Number: 1565 • ACR Convergence 2025
Association of the gastrointestinal (GI) microbiome and GI symptoms in systemic sclerosis: An international, multi-center, observational study
Zsuzsanna McMahan¹, Swapna Joshi², Jennifer Labus², Arissa Young², Andrea Low³, Vanessa Smith⁴, Susanna Proudman⁵, Antonia Valenzuela⁶, Phoebe Hunter⁷, Kristofer Andréasson⁸, Ezinne Aja², Jonathan Jacobs² and Elizabeth Volkmann⁹, ¹UT Health Houston, Houston, TX, ²UCLA, Los Angeles, ³Singapore General Hospital, SingHealth; Duke-NUS, Singapore, Singapore, ⁴Ghent University Hospital, Gent, Belgium, ⁵Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁶Pontificia Universidad Catolica de Chile, Santiago, Chile, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ⁹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: GI disease is highly prevalent in systemic sclerosis (SSc) and adversely affects quality of life and survival in SSc. The pathogenesis of GI disease…
Abstract Number: 1519 • ACR Convergence 2025
Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
Anca Askanase¹, Bruno Flamion², Ouali Berkani² and Cecile Dubois², ¹Columbia University Medical Center, New York, NY, ²Viatris Innovation, Allschwil, Switzerland
Background/Purpose: Cenerimod is a highly selective S1P1 receptor modulator which is undergoing trials for potential therapeutic benefits in autoimmune disease, including Systemic Lupus Erythematous (SLE).…
Abstract Number: 1557 • ACR Convergence 2025
Association between Thoracic Muscle and Fat Area and Density and Pulmonary Function in Systemic Sclerosis
Aradhna Agarwal¹, Niki Pradhan¹, James St. Clair², Dinesh Khanna³ and Elana Bernstein⁴, ¹Columbia University Medical Center, New York, NY, ²University of Michigan, Ann Arbor, ³University of Michigan, Ann Arbor, MI, ⁴Columbia University, New York, NY
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis (SSc). Little is known about the association between body composition and…
Abstract Number: 1596 • ACR Convergence 2025
GPA-Associated Tracheobronchial Stenosis: Immunosuppressant Use and Dilation Frequency
Brendan Denvir¹, Alexander Hillel², Ami Shah³, Ji Soo Kim¹, Philip Seo² and Brendan Antiochos⁴, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Johns Hopkins, CLARKSVILLE, MD
Background/Purpose: Granulomatosis with polyangiitis (GPA) is an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis that affects all levels of the respiratory tract. Tracheobronchial stenosis (TBS) occurs in…
Abstract Number: 1575 • ACR Convergence 2025
Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.
Kevin Chevalier¹, Brigitte Bader-Meunier², Isabelle Kone-Paut³, Benjamin Torreau⁴, Marc Michel⁵, Bertrand Godeau⁵, Christian AGARD⁶, Thomas Papo⁷, Karim Sacré⁸, Raphaele Seror⁹, Xavier Mariette¹⁰, Cacoub Patrice¹¹, Ygal Benhamou¹², Mathilde Leclercq¹³, Cécile goujard¹⁴, Olivier Lambotte³, Bernard Bonnotte¹⁵, Maxime Samson¹⁶, Félix Ackermann¹⁷, Jean Schmidt¹⁸, Pierre Duhaut¹⁸, Jean-Emmanuel Kahn¹⁹, Thomas Hanslik¹⁹, Nathalie Costedoat-Chalumeau²⁰, Benjamin Terrier²⁰, Alexis REGENT²¹, bertrand Dunogue²², Pascal Cohen²³, Véronique Le Guern²⁰, Eric HACHULLA²⁴, Luc Mouthon²² and Benjamin Chaigne²², ¹Université Paris Cité, Montrouge, France, ²Necker hospital, Paris, France, ³Bicêtre hospital, Kremlin Bicêtre, France, ⁴Internal Medicine and Immunology, CHU Tours, Tours, France, ⁵Henri Mondor hospital, Créteil, France, ⁶Internal medicine, Nantes University Hospital, Nantes, France, ⁷Bichat hospital, Paris, France, ⁸Department of Internal Medicine, Bichat University Hospital, Université Paris Cité, AP-HP, Paris, France, Paris, France, ⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ¹⁰Université Paris-Saclay, Le Kremlin Bicetre, France, ¹¹Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S⁹⁵⁹, Immunology-Immunopathology-Immunotherapy (I³), Paris, France, Paris, France, ¹²Internal Medicine, CHU Rouen, Rouen, France, ¹³Rouen hospital, Rouen, France, ¹⁴Université Paris Saclay, Department of Internal Medicine and Clinical Immunology, Bicêtre Hospital, APHP, UMR¹¹⁸⁴ Inserm, CEA, Le Kremlin Bicêtre, France, Kremlin Bicêtre, France, ¹⁵Internal medicine and clinical immunology, Université Bourgogne Europe , CHU Dijon Bourgogne, Dijon, France, ¹⁶CHU Dijon Bourgogne, Dijon, France, ¹⁷Foch hospital, Suresnes, France, ¹⁸Amiens hospital, Amiens, France, ¹⁹Ambroise Paré hospital, Boulogne, France, ²⁰Cochin hospital, Paris, France, ²¹Hopital Cochin, Paris, France, ²²Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ²³Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ²⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-Immunes et Auto-Inflammatoires Rares du Nord, Nord-Ouest, Méditerranée et Guadeloupe (CeRAINOM), Lille, France, Lille, France
Background/Purpose: Mixed connective tissue disease (MCTD) is an entity defined by clinical features of differentiated connective tissue diseases (dCTD), such as systemic lupus erythematosus (SLE),…
Abstract Number: 1602 • ACR Convergence 2025
Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis
Irene Carrión-Barberà¹, Jorge A. Gonzalez-Chapa², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Paul Monach⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Ulrich Specks¹², Kenneth Warrington¹², Peter Merkel⁷ and Christian Lood², ¹Department of Rheumatology. Hospital del Mar, Barcelona, Spain, ²University of Washington, Division of Rheumatology, Seattle, ³University of South Florida, Tampa, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Moreland Hills, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸VA Boston Healthcare System, Boston, MA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic, Rochester, MN
Background/Purpose: Innate immune activation plays a key role in granulomatosis with polyangiitis (GPA), contributing to vascular inflammation via neutrophil extracellular traps, immune complexation (IC), and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].